Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(64), 2020

DOI: 10.1128/aac.00342-20

Links

Tools

Export citation

Search in Google Scholar

Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model

Journal article published in 2020 by Iain J. Abbott ORCID, Elke van Gorp, Aart van der Meijden, Rixt A. Wijma, Joseph Meletiadis, Jason A. Roberts ORCID, Johan W. Mouton ORCID, Anton Y. Peleg
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against E. faecalis and E. faecium isolates using a dynamic in vitro bladder infection model. Eighty-four isolates underwent fosfomycin agar dilution susceptibility testing ( E. faecalis MIC 50/90 32/64 μg/ml; E. faecium MIC 50/90 64/128 μg/ml).